中华麻醉学杂志
中華痳醉學雜誌
중화마취학잡지
CHINESE JOURNAL OF ANESTHESIOLOGY
2009年
10期
873-876
,共4页
张哲%张铁铮%周锦%王富江%徐兆新%张悦
張哲%張鐵錚%週錦%王富江%徐兆新%張悅
장철%장철쟁%주금%왕부강%서조신%장열
哌啶类%脑%心肺转流术%冠状动脉分流术
哌啶類%腦%心肺轉流術%冠狀動脈分流術
고정류%뇌%심폐전류술%관상동맥분류술
Piperidines%Brain%Cardiopulmonary bypass%Coronary artery bypass
目的 探讨瑞芬太尼预处理对冠状动脉旁路移植术患者体外循环期间的脑保护作用.方法 择期行体外循环(CPB)冠状动脉旁路移植术的患者40例,ASA Ⅱ或Ⅲ级,随机分为4组(n=10):对照组(C组)和不同剂量瑞芬太尼预处理组(R_(1~3)组).R_(1~3)组于麻醉诱导后30 min时分别静脉输注瑞芬太尼0.6、1.2和1.8 μg·kg~(-1)min~(-1),输注时间5 min,重复3次,间隔5 min;C组以生理盐水代替瑞芬太尼.于麻醉诱导前(T_0)、CPB开始前(T_1)、CPB 30 min(T_2)、CPB结束(T_3)时取颈内静脉血样3 ml,采用ELISA法测定血浆S-100β蛋白浓度,采用比色法测定血浆超氧化物歧化酶(SOD)活性和丙二醛(MDA)浓度.结果 与T_0时比较,T_(1~3)时各组血浆S-100β蛋白和MDA浓度升高,SOD活性降低(P<0.05或0.01);与C组比较,R_3组T_(2,3)时血浆S-100β蛋折和MDA浓度降低,SOD活性升高(P<0.05),R_1组和R_2组上述指标差异无统计学意义(P>0.05).结论 瑞芬太尼(1.8μg·kg~(-1)min~(-1))预处理可减轻冠状动脉旁路移植术患者CPB诱发脑损伤,其机制可能与抑制脑脂质过氧化反应有关.
目的 探討瑞芬太尼預處理對冠狀動脈徬路移植術患者體外循環期間的腦保護作用.方法 擇期行體外循環(CPB)冠狀動脈徬路移植術的患者40例,ASA Ⅱ或Ⅲ級,隨機分為4組(n=10):對照組(C組)和不同劑量瑞芬太尼預處理組(R_(1~3)組).R_(1~3)組于痳醉誘導後30 min時分彆靜脈輸註瑞芬太尼0.6、1.2和1.8 μg·kg~(-1)min~(-1),輸註時間5 min,重複3次,間隔5 min;C組以生理鹽水代替瑞芬太尼.于痳醉誘導前(T_0)、CPB開始前(T_1)、CPB 30 min(T_2)、CPB結束(T_3)時取頸內靜脈血樣3 ml,採用ELISA法測定血漿S-100β蛋白濃度,採用比色法測定血漿超氧化物歧化酶(SOD)活性和丙二醛(MDA)濃度.結果 與T_0時比較,T_(1~3)時各組血漿S-100β蛋白和MDA濃度升高,SOD活性降低(P<0.05或0.01);與C組比較,R_3組T_(2,3)時血漿S-100β蛋摺和MDA濃度降低,SOD活性升高(P<0.05),R_1組和R_2組上述指標差異無統計學意義(P>0.05).結論 瑞芬太尼(1.8μg·kg~(-1)min~(-1))預處理可減輕冠狀動脈徬路移植術患者CPB誘髮腦損傷,其機製可能與抑製腦脂質過氧化反應有關.
목적 탐토서분태니예처리대관상동맥방로이식술환자체외순배기간적뇌보호작용.방법 택기행체외순배(CPB)관상동맥방로이식술적환자40례,ASA Ⅱ혹Ⅲ급,수궤분위4조(n=10):대조조(C조)화불동제량서분태니예처리조(R_(1~3)조).R_(1~3)조우마취유도후30 min시분별정맥수주서분태니0.6、1.2화1.8 μg·kg~(-1)min~(-1),수주시간5 min,중복3차,간격5 min;C조이생리염수대체서분태니.우마취유도전(T_0)、CPB개시전(T_1)、CPB 30 min(T_2)、CPB결속(T_3)시취경내정맥혈양3 ml,채용ELISA법측정혈장S-100β단백농도,채용비색법측정혈장초양화물기화매(SOD)활성화병이철(MDA)농도.결과 여T_0시비교,T_(1~3)시각조혈장S-100β단백화MDA농도승고,SOD활성강저(P<0.05혹0.01);여C조비교,R_3조T_(2,3)시혈장S-100β단절화MDA농도강저,SOD활성승고(P<0.05),R_1조화R_2조상술지표차이무통계학의의(P>0.05).결론 서분태니(1.8μg·kg~(-1)min~(-1))예처리가감경관상동맥방로이식술환자CPB유발뇌손상,기궤제가능여억제뇌지질과양화반응유관.
Objective To investigate the cerebral protective effect of remifentanil preconditioning during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting (CABG). Methods Forty ASA Ⅱ or Ⅲ patients of both sexes aged 55-64 yr weighing 50-85 kg undergoing elective CABG were randomized into 4 groups (n = 10 each) : control group (group C) and remifentanil groups (group R_1, R_2, R_3). Anasthesia was induced with midazolam 0.04 mg/kg, remifentanil 1 μg/kg, propofol 1 mg/kg and pipecuronium 0.1 mg/kg and maintained with isoflurane inhalation,intravenous continuous propofol infusion at 6-10 mg·kg~(-1)·h~(-1) and intermittent iv boluses of sufentanil and pipecurpnium after tracheal intubation. The patients were mechanically ventilated. P_(ET) CO_2 was maintained at 35-45 mm Hg. A catheter was inserted into internal jugular vein and advanced cranially until jugular bulb for blood sampling. The remifentanil groups received three 5 min episodes of iv remifentanil infusion at 0.6 μg/kg~(-1) ·min(-1) (group R_1),1.2μg/kg~(-1) ·min(-1)(group R_2) and 1.8μg/kg~(-1) ·min(-1)(group R_3) at 5 min intervals after induction of anesthesia before operation.Blood samples were obtained from jugular bulb before induction of anesthesia (T_0, baseline), before CPB (T_1), 30 min after initiation of CPB (T_2) and at the end of CPB (T_3) for determination of plasma S-100βprotein and MDA concentrations arid SOD activity. Results Plasma S-100β protein and MDA concentrations were significantly increased while plasma SOD activity was significantly decreased at T<1-3> as compared with the baseline values at T_0 in all 4 groups. Plasma S-100β protein and MDA concentrations were significantly lower while plasma SOD activity was significantly higher at T_2 and T_3 in group R_3 than in the other 3 groups. Conclusion Preconditioning with larger doses of remifentanil (1.8 μg/kg~(-1) ·min(-1)) can attenuate brain injury induced by CPB in patient undergoing CABG through inhibiting oxidative stress response.